International Journal of Hematology

, 78:439

MLL/AF-1p Fusion in Therapy-Related Early Pre-B Acute Lymphoblastic Leukemia with t(1;11)(p32;q23) Translocation Developing in the Relapse Phase of Acute Promyelocytic Leukemia

Authors

    • Division of Hematology, Department of MedicineKawasaki Medical School
  • Hideho Wada
    • Division of Hematology, Department of MedicineKawasaki Medical School
  • Shunji Yamamori
    • Mitsubishi Kagaku Bio-clinical Laboratories
  • Takemi Otsuki
    • Department of HygieneKawasaki Medical School
  • Sinichiro Suemori
    • Division of Hematology, Department of MedicineKawasaki Medical School
  • Toshinori Kondo
    • Division of Hematology, Department of MedicineKawasaki Medical School
  • Hidekazu Nakanishi
    • Division of Hematology, Department of MedicineKawasaki Medical School
  • Yoshimasa Suetsugu
    • Division of Hematology, Department of MedicineKawasaki Medical School
  • Makoto Mikami
    • Division of Hematology, Department of MedicineKawasaki Medical School
  • Takashi Sugihara
    • Division of Hematology, Department of MedicineKawasaki Medical School
Case Report

DOI: 10.1007/BF02983817

Cite this article as:
Tsujioka, T., Wada, H., Yamamori, S. et al. Int J Hematol (2003) 78: 439. doi:10.1007/BF02983817

Abstract

We report the development of therapy-related early pre-B acute lymphoblastic leukemia in a patient administered a topoisomerase II inhibitor, etoposide, a consolidation therapy agent for acute promyelocytic leukemia. Our case is of interest because of simultaneous relapse of the original leukemia and onset of therapy-related leukemia and relatively rare t(1;11) (p32;q23) translocation with confirmedMLL/AF- 1p fusion. This case suggests that careful monitoring forMLL gene rearrangements is necessary after administration of topoisomerase II inhibitors.

Key words

Therapy-related AL MLL AF- 1p FISH

Copyright information

© The Japanese Society of Hematology 2003